Catabasis Pharmaceuticls Inc. (CATB) Sees Large Volume Increase
Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) saw an uptick in trading volume on Tuesday . 413,376 shares traded hands during mid-day trading, an increase of 695% from the previous session’s volume of 51,978 shares.The stock last traded at $4.06 and had previously closed at $3.96.
Several brokerages have issued reports on CATB. Oppenheimer Holdings Inc. reissued an “outperform” rating and issued a $28.00 target price on shares of Catabasis Pharmaceuticls in a research report on Wednesday, May 25th. Wedbush reissued an “outperform” rating and issued a $17.00 target price on shares of Catabasis Pharmaceuticls in a research report on Friday, August 12th. Zacks Investment Research cut Catabasis Pharmaceuticls from a “buy” rating to a “hold” rating in a research report on Monday, July 18th. Finally, Cowen and Company reissued a “buy” rating on shares of Catabasis Pharmaceuticls in a research report on Wednesday, June 8th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Catabasis Pharmaceuticls has a consensus rating of “Buy” and a consensus price target of $19.05.
The company has a 50-day moving average of $4.70 and a 200-day moving average of $4.88. The company’s market cap is $63.68 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/catabasis-pharmaceuticls-inc-catb-sees-large-volume-increase.html
Catabasis Pharmaceuticls (NASDAQ:CATB) last released its quarterly earnings results on Thursday, August 11th. The company reported ($0.61) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.04. On average, analysts expect that Catabasis Pharmaceuticls Inc. will post ($2.47) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sphera Funds Management LTD. raised its position in Catabasis Pharmaceuticls by 184.9% in the first quarter. Sphera Funds Management LTD. now owns 230,041 shares of the company’s stock valued at $1,159,000 after buying an additional 149,299 shares during the last quarter. Rhenman & Partners Asset Management AB raised its position in Catabasis Pharmaceuticls by 12.7% in the first quarter. Rhenman & Partners Asset Management AB now owns 345,100 shares of the company’s stock valued at $1,739,000 after buying an additional 38,873 shares during the last quarter. Finally, Bridgeway Capital Management Inc. bought a new position in Catabasis Pharmaceuticls during the second quarter valued at approximately $102,000. 66.58% of the stock is owned by hedge funds and other institutional investors.
About Catabasis Pharmaceuticls
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related companies with MarketBeat.com's FREE daily email newsletter.